Sign In
Buy URGN
$38.24
-2.85 (-6.94%)
At Close: Jul 31, 2026
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the
UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd.
08:15am, Monday, 16'th Jun 2025
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) inves
July 28, 2025 Deadline Approaching: Join Class Action Against UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky
07:35am, Monday, 16'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against UroGen
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd.
05:45am, Monday, 16'th Jun 2025
NEW YORK , June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN).
Lost Money on UroGen Pharma Ltd. (URGN)? Join Class Action Before July 28, 2025 - Contact Levi & Korsinsky
11:00pm, Sunday, 15'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
URGN ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against UroGen Pharma Ltd. - July 28, 2025 Deadline
10:55am, Sunday, 15'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
10:17am, Sunday, 15'th Jun 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In UroGen To Contact Him Directly To Discuss Their Options If you suff
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such inve
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025 - Contact Levi & Korsinsky
07:55am, Sunday, 15'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against UroGen
Class Action Lawsuit Filed Against UroGen Pharma Ltd. (URGN) - Recover Losses - Contact Levi & Korsinsky Before July 28, 2025
06:50am, Sunday, 15'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
Class Action Lawsuit Filed Against UroGen Pharma Ltd. (URGN) - Recover Losses - Contact Levi & Korsinsky Before July 28, 2025
06:25pm, Saturday, 14'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 14, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the
UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
06:15pm, Friday, 13'th Jun 2025
Goldman Sachs analyst Paul Choi raised the firm's price target on UroGen Pharma to $16 from $3 and keeps a Neutral rating on the shares following yesterday's approval of Zusduri. The firm cites the st
